Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Guam Technology Journal.
Press releases published on June 30, 2025
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities
GlobeNewswire
·
June 30, 2025
SEATTLE and VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of …
COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders
GlobeNewswire
·
June 30, 2025
TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and …
Shoals Technologies Group, Inc. Announces Battery Energy Storage Systems (“BESS”) Webinar
GlobeNewswire
·
June 30, 2025
PORTLAND, Tenn., June 30, 2025 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a global leader in electrical balance of systems (“EBOS”) solutions for the energy transition market, announced today that it has …
Acesis Biomed Secures Patents Advancing Testosterone-Inducing Drug Development
GlobeNewswire
·
June 30, 2025
Centennial, Colorado, June 30, 2025 (GLOBE NEWSWIRE) -- Acesis Holdings Corporation (“Acesis Biomed”), a pre-clinical stage biomedical company pioneering oral treatments for metabolic and endocrine disorders linked to low testosterone, today announced a …
Avicanna Announces Results of Annual General Meeting
GlobeNewswire
·
June 30, 2025
TORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based …
Aptose Announces Deferral of Interest Payment
GlobeNewswire
·
June 30, 2025
SAN DIEGO and TORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat …
Earn Up to $1,000,000 a Day with BTC Miner – 100% Guaranteed Profits
GlobeNewswire
·
June 30, 2025
New York City, NY, June 30, 2025 (GLOBE NEWSWIRE) -- Amid ongoing market volatility in the cryptocurrency sector, investors are increasingly turning to platforms that offer greater stability and predictable returns. BTC Miner has emerged as a game-changing …
DataGrail Report: Consumer Demand for Data Privacy Surges, Driving Up Business Costs as Data Deletion Requests Rise
GlobeNewswire
·
June 30, 2025
SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- Consumers are reclaiming control of their personal data—and businesses are feeling the impact. DataGrail’s newly released 2025 Data Privacy Trends Report shows a surge in data deletion and do not share …
Mensa IQ Test - Free International Mensa IQ Quiz with Instant Results Now Offered by QuickIQTest.org
GlobeNewswire
·
June 30, 2025
New York City, June 30, 2025 (GLOBE NEWSWIRE) -- QuickIQTest.org, a trusted leader in online cognitive assessments, proudly announces the official launch of its Free Mensa IQ Test 2025. Designed to closely mirror the structure and rigor of a Mensa …
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 30, 2025
BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat cancers, reported today that Pyxis Oncology’s …
Progress Software Acquires Nuclia, an Innovator in Agentic RAG AI Technology
GlobeNewswire
·
June 30, 2025
Company adds easy-to-use agentic RAG-as-a-service product for organizations to automate and retrieve verifiable, high-quality AI search and generative answers BURLINGTON, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Progress Software (Nasdaq: PRGS), the …
INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GlobeNewswire
·
June 30, 2025
Boca Raton, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has closed its registered direct offering, announced on June 27, 2025, (the …
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire
·
June 30, 2025
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has …
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
GlobeNewswire
·
June 30, 2025
As of June 30th, 16 participants have enrolled in the Phase 1b, ahead of the original goal of at least 15 total participants by 3Q 2025 Analysis of 90-day biomarker activity from cerebrospinal fluid (CSF) in all participants currently enrolled is now …
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
GlobeNewswire
·
June 30, 2025
Long-term efficacy and safety data on PALSONIFYTM (paltusotine) in acromegaly to be presented, including evidence of both biochemical and symptom control with a well-tolerated safety profile in patients switching treatments and those not previously …
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
GlobeNewswire
·
June 30, 2025
- $100 million funded upfront; additional $175 million tied to milestones provides strategic flexibility through key inflection points - WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company …
I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research
GlobeNewswire
·
June 30, 2025
Monotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy ROCKVILLE, MD, June 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech …
Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery
GlobeNewswire
·
June 30, 2025
PWR delivers science-driven cellular energy and recovery support as part of Jupiter’s expanding longevity supplement portfolio Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a …
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
GlobeNewswire
·
June 30, 2025
Contribution highlights leadership’s understanding of the importance AI will play in drug discovery WARREN, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that founder and Chief …
KnowBe4 Announces New Assessment Tool to Enable Data-Driven Security Culture Improvements
GlobeNewswire
·
June 30, 2025
TAMPA BAY, FL, June 30, 2025 (GLOBE NEWSWIRE) -- KnowBe4, the world-renowned cybersecurity platform that comprehensively addresses human risk management, released today the KnowBe4 Program Maturity Assessment (PMA), a free, strategic tool designed to help …